GLP-3RT
MedTech Research Group
Research Hub — Aggregated Studies
MedTech Research Group aggregates published research from peer-reviewed journals, clinical trials, and academic institutions. We do not conduct original research. All studies cited below are the work of their respective authors and institutions. Sources are linked for verification.
This product is designated FOR RESEARCH USE ONLY (RUO). These compounds have not been approved or cleared under 21 U.S.C. § 505 and have not been evaluated by the FDA for safety, efficacy, or labeling for clinical, diagnostic, or therapeutic use in humans or animals.
MedTech Research Group will only fulfill orders to qualified researchers affiliated with accredited academic institutions, licensed research facilities, or organizations with active IRB/IACUC oversight.
Purchaser Restrictions
- Purchaser must be a qualified researcher at an accredited institution or licensed research facility
- This product may not be sold or redistributed to individual consumers, wellness clinics, health food stores, or retail establishments
- Not intended for human or animal consumption, diagnostic use, or therapeutic application
- Institutional affiliation and research purpose will be verified prior to order fulfillment
Distribution is limited to qualified research use in compliance with applicable federal and state law. These products bear the "For Research Use Only" designation per FDA labeling requirements (minimum 10 pt. font). Ref: 21 U.S.C. § 505; FD&C Act § 201(p) (unapproved new drug definition).
| Risk Tier | YELLOW |
| Category | Metabolic / Gastrointestinal |
| Subcategory | Multi-Receptor Metabolic Regulation |
| Pharmacological Class | Peptide Hormone Analog |
| Subclass | Novel GLP Receptor Agonist (proprietary designation) |
| Molecular Type | Modified Peptide |
| Origin | Synthetic |
| Regulatory Status | Research Use Only. Not FDA-approved. Proprietary compound designation. |
| Route of Administration | Subcutaneous injection |
| Reconstitution | Lyophilized powder; reconstitute with bacteriostatic water |
| Storage | Refrigerate (2-8°C) |
Description
GLP-3RT is a proprietary peptide compound designation used within the YPB product catalog. The "GLP" prefix indicates it belongs to the glucagon-like peptide family of receptor-targeting compounds, while the "RT" suffix and "3" designation suggest a next-generation formulation that may target multiple receptors in the incretin and metabolic signaling pathways. Specific structural and pharmacological details for GLP-3RT are proprietary to the manufacturer and are not published in peer-reviewed literature under this exact designation.
What is clear from the YPB network sales data is that GLP-3RT is by far the highest-volume product in the catalog. Across the YPB reseller network (September 2025 through April 2026), GLP-3RT accounted for 66% of total network revenue — approximately $496,000 from 7,345 units sold across 86 stores. The 20mg formulation (YPB.210) alone generated $249,000 in revenue over 7 months. This level of market demand, combined with strong margins (65-72% at Premier pricing), makes GLP-3RT the single most commercially important product in the catalog.
The product is available in an unusually wide range of dosing options (10mg through 60mg in the PLDS catalog, and 12mg/24mg in the Standard catalog), suggesting clinical research applications that require flexible titration and various protocol durations.
Clinical Context
GLP-3RT is the dominant product in the YPB reseller network by a wide margin. Its proprietary designation and lack of published literature under this name mean that researchers should consult manufacturer documentation for detailed pharmacological characterization. The wide range of available sizes (10mg through 60mg) and the strong market demand across 86 stores suggest broad research utility in metabolic and glycemic regulation studies.
- This is a proprietary designation; consult manufacturer documentation for complete pharmacological profile
- Safety profile expected to be consistent with other GLP-family receptor agonists (GI side effects, titration requirements)
- The wide size range (10mg-60mg) facilitates various research protocol designs
- Highest-volume product across the YPB network — strong market validation of demand
Published Research
Published Research & Clinical Data
Peer-reviewed studies and clinical trial data related to GLP-3RT
All research below is conducted by independent institutions. MedTech Research Group provides these references for informational purposes only.
Research citations are being compiled for this compound.
Check back soon — our team is curating peer-reviewed sources.